A new drug for treating early-stage Alzheimer’s disease has been administered for the first time in Taiwan on an 83-year-old ...

The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

Jim Rogers, 58, was living and working in Australia when he started to develop symptoms of the incurable neurological ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

On Friday, the European Medicines Agency recommended that Lilly’s Kisunla not receive marketing authorization because its benefits don’t outweigh its potential risks. Clinical trials have shown ...

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...

This authorization is specifically for patients who are Apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. Kisunla, an amyloid-targeting therapy, is now the first of its kind registered in ...

Australia's competition watchdog said on Wednesday that Singapore Telecommunications-owned Optus has reached a settlement ...